ZANTAC 300 Drug Patent Profile
✉ Email this page to a colleague
When do Zantac 300 patents expire, and when can generic versions of Zantac 300 launch?
Zantac 300 is a drug marketed by Glaxosmithkline and Glaxo Grp Ltd and is included in two NDAs.
The generic ingredient in ZANTAC 300 is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zantac 300
A generic version of ZANTAC 300 was approved as ranitidine hydrochloride by SANDOZ on August 29th, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZANTAC 300?
- What are the global sales for ZANTAC 300?
- What is Average Wholesale Price for ZANTAC 300?
Summary for ZANTAC 300
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 35 |
Clinical Trials: | 22 |
Patent Applications: | 2,243 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ZANTAC 300 at DailyMed |
![ZANTAC 300 drug patent expirations Drug patent expirations by year for ZANTAC 300](/p/graph/s/t/ZANTAC_300-patent-expirations.png)
Recent Clinical Trials for ZANTAC 300
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Food and Drug Administration (FDA) | Phase 1 |
Spaulding Clinical Research LLC | Phase 1 |
Nova Scotia Health Authority | Phase 4 |
US Patents and Regulatory Information for ZANTAC 300
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | ZANTAC 300 | ranitidine hydrochloride | CAPSULE;ORAL | 020095-002 | Mar 8, 1994 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Glaxo Grp Ltd | ZANTAC 300 | ranitidine hydrochloride | TABLET;ORAL | 018703-002 | Dec 9, 1985 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZANTAC 300
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxo Grp Ltd | ZANTAC 300 | ranitidine hydrochloride | TABLET;ORAL | 018703-002 | Dec 9, 1985 | ⤷ Sign Up | ⤷ Sign Up |
Glaxo Grp Ltd | ZANTAC 300 | ranitidine hydrochloride | TABLET;ORAL | 018703-002 | Dec 9, 1985 | ⤷ Sign Up | ⤷ Sign Up |
Glaxosmithkline | ZANTAC 300 | ranitidine hydrochloride | CAPSULE;ORAL | 020095-002 | Mar 8, 1994 | ⤷ Sign Up | ⤷ Sign Up |
Glaxosmithkline | ZANTAC 300 | ranitidine hydrochloride | CAPSULE;ORAL | 020095-002 | Mar 8, 1994 | ⤷ Sign Up | ⤷ Sign Up |
Glaxo Grp Ltd | ZANTAC 300 | ranitidine hydrochloride | TABLET;ORAL | 018703-002 | Dec 9, 1985 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZANTAC 300
See the table below for patents covering ZANTAC 300 around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Denmark | 167794 | ⤷ Sign Up | |
Ireland | 45456 | ⤷ Sign Up | |
Austria | 381937 | ⤷ Sign Up | |
Portugal | 73744 | PROCESS FOR PREPARING AMINOALKYL FURAN DERIVATIVE | ⤷ Sign Up |
Ireland | 63179 | Pharmaceutical capsules containing ranitidine | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |